ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SLP Simulations Plus Inc

36.42
-0.59 (-1.59%)
15 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Simulations Plus Inc NASDAQ:SLP NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.59 -1.59% 36.42 28.01 41.00 37.665 36.26 37.36 108,426 01:00:00

Simulations Plus to Participate in the BTIG Digital Health Forum

19/11/2024 1:30pm

Business Wire


Simulations Plus (NASDAQ:SLP)
Historical Stock Chart


From Nov 2024 to Feb 2025

Click Here for more Simulations Plus Charts.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O’Connor will join a panel discussion entitled “Supporting Drug Development, Clinical Trials, and Biopharma” at 2:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings throughout the day.

For more information about the BTIG Digital Health Forum, or to register to attend, please visit the BTIG website. For more information about the event, email uscorporateaccess@btig.com. Please note that participants must be pre-registered to attend.

About Simulations Plus

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | X | YouTube.

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2023 ESG update.

Simulations Plus Investor Relations Cristin Ryman 984-444-8358 cristin.ryman@simulations-plus.com

Financial Profiles Lisa Fortuna 310-622-8251 slp@finprofiles.com

1 Year Simulations Plus Chart

1 Year Simulations Plus Chart

1 Month Simulations Plus Chart

1 Month Simulations Plus Chart

Your Recent History

Delayed Upgrade Clock